Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
FAIL · Does not pass the screen
37.00 USD
At the last full screen 2026-08-26
Screened 2026-08-26 · the tape above runs as of 10:31 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its accumulation label.
Pharvaris N.V. holds its Accumulation at $37.00. Consolidating, no directional conviction, held for 100 days.
As held on the ledger · 2026-08-26
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 100 days
Price at the screen
$37.00
Valuation
N/A trailing · -11.84 forward price to earnings
Values screen
FAIL· score 70.0
Beta
-2.33
The Workings
Five Screens, Shown in Full
Does not pass. Accounts receivable
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.26%
Below 33%
Interest-bearing debt is just 0.3% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
98.27%
Below 49%
Money owed to the company is 98.3% of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-26 screen. The gold marker is the market price at the same screen. A 30.3% margin of safety to the base estimate.
Third-party analyst targets: 14 covering, consensus Strong Buy. The average target sits +30% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-26 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Biotech with zero profits fails basic checks
Picture a late stage drug developer racing to treat rare swelling disorders. The science may one day matter, yet the company posts a zero profit margin and a negative seventy three percent return on equity. With no usable financial ratios available, it fails the ethical screen outright and earns an opportunity rating of none. We therefore pass.
The forward price to earnings ratio sits at negative twelve point five times, which simply reflects ongoing losses rather than any bargain. Fourteen analysts may favour the name and set a median target well above the current share price, but missing data on margins and returns leaves the investment case untestable by our standards.
Development timelines in rare disease biotech are long and binary, with cash burn that can stretch for years before any product reaches patients. Currency and regulatory risks add further uncertainty. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to Switzerland and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PHVS trades on Nasdaq (the company is based in Switzerland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (13 analysts) rates it strong buy, with a mean price target of $47.
2026-08-08Markup · changed$34.91+13.6%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (13 analysts) rates it strong buy, with a mean price target of $47.
2026-07-18Accumulation$30.72+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 16% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 74%. Our forward projection puts the odds of a 10% gain over the next month near 33%. The street (13 analysts) rates it strong buy, with a mean price target of $47.
2026-07-03Accumulation$30.72+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$30.72Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
